UBS Group’s Novo Integrated Sciences, Inc. Common Stock NVOS Stock Holding History

UBS Group’s Portfolio NVOS Stock Details NVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-48,752	Closed	-$13.7K	–	10777
2024 Q3	$13.7K	Buy	48,752 +17,690	+57%	+$8.26K	﹤0.01%	7576
2024 Q2	$23.3K	Buy	+31,062	New	+$19.9K	﹤0.01%	7207
2024 Q1	–	Sell	-12,113	Closed	-$9.95K	–	10448
2023 Q4	$9.95K	Buy	+12,113	New	+$24.6K	﹤0.01%	7461
2023 Q3	–	Sell	-13,814	Closed	-$20.4K	–	10218
2023 Q2	$20.4K	Buy	+13,814	New	+$18.8K	﹤0.01%	6857
2023 Q1	–	Sell	-1,239	Closed	-$2.48K	–	10996
2022 Q4	$2.48K	Buy	1,239 +1,126	+996%	+$3.87K	﹤0.01%	9671
2022 Q3	$1K	Sell	113 -15	-12%	-$244	﹤0.01%	10148
2022 Q2	$2K	Buy	+128	New	+$2.61K	﹤0.01%	9691
2021 Q2	–	Sell	-254	Closed	-$9K	–	10000
2021 Q1	$9K	Buy	+254	New	+$10.6K	﹤0.01%	8034

Other funds holding NVOS

ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return

UBS Group's NVOS Position: Q4 2024 in Review

UBS Group sold out of Novo Integrated Sciences, Inc. Common Stock (NVOS) in Q4 2024, closing a stake of 48,752 shares — an estimated $13.7K sold.

UBS Group first reported a position in NVOS in Q1 2021 and held it in 8 quarters. The position peaked at $23.3K in Q2 2024. 1 fund tracked by Wall St. Rank holds NVOS as of Q4 2024.

UBS Group reported no remaining Novo Integrated Sciences, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
UBS Group sold 48,752 Novo Integrated Sciences, Inc. Common Stock shares in Q4 2024, an estimated $13.7K.
UBS Group first reported a position in Novo Integrated Sciences, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
UBS Group's Novo Integrated Sciences, Inc. Common Stock position peaked at $23.3K in Q2 2024.
1 fund tracked by Wall St. Rank held Novo Integrated Sciences, Inc. Common Stock as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.